Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMIKIN vs METHERGINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.
Methylergonovine is an ergot alkaloid that acts as a partial agonist at α-adrenergic receptors in the uterine smooth muscle, causing sustained contractions. It also exhibits serotonergic (5-HT2) and dopaminergic activity.
Treatment of serious gram-negative bacterial infections,Infections caused by susceptible strains of Pseudomonas aeruginosa, Escherichia coli, Proteus, Klebsiella, Serratia, and Enterobacter
Prevention and treatment of postpartum hemorrhage due to uterine atony,Management of incomplete abortion
15 mg/kg/day IV or IM divided every 8 to 12 hours; usual adult dose: 15 mg/kg/day
0.2 mg intramuscularly or intravenously after delivery of placenta and every 2-4 hours as needed, up to a maximum of 5 doses.
2-3 hours in adults with normal renal function; prolonged to 30-90 hours in ESRD.
Terminal elimination half-life is approximately 2–3 hours in healthy adults; prolonged in hepatic impairment.
Amikacin is not metabolized; it is excreted unchanged primarily by glomerular filtration.
Primarily hepatic via CYP3A4 with significant first-pass metabolism; active metabolite is methylergonovine itself; excreted mainly in bile and urine.
Renal: >90% unchanged in urine via glomerular filtration; biliary/fecal: <1%.
Primarily hepatic metabolism; less than 1% excreted unchanged in urine. Biliary/fecal excretion accounts for ~80% of metabolites.
0-10% (low binding to albumin).
Approximately 93% bound, primarily to albumin and alpha-1-acid glycoprotein.
0.25 L/kg in adults; higher in neonates and edema states (0.3-0.4 L/kg), indicating distribution into extracellular fluid.
0.6 L/kg (range 0.3–0.8 L/kg), indicating moderate distribution into tissues.
IM: 100% (complete absorption); oral: <1% (not absorbed).
Oral bioavailability is approximately 10–20% due to extensive first-pass metabolism. Intramuscular administration provides 100% bioavailability.
GFR 30-59 m L/min: extend dosing interval to every 12-24 hours; GFR 15-29 m L/min: extend to every 24-48 hours; GFR <15 m L/min: extend to every 48-72 hours or consider peritonitis dosing; adjust based on serum levels
No specific dose adjustment recommended; use with caution in renal impairment due to risk of hypertension.
No specific Child-Pugh based adjustments required; amikacin is minimally hepatically metabolized; monitor renal function as primary clearance route
Contraindicated in severe hepatic impairment (Child-Pugh class C). For Child-Pugh class A or B, use with caution and monitor for signs of toxicity.
Neonates: 15-20 mg/kg/day IV/IM every 12-24 hours depending on gestational age; Infants and children: 15-22.5 mg/kg/day divided every 8-12 hours; maximum 1.5 g/day
Not recommended for pediatric use; safety and efficacy in children have not been established.
Start with lower initial doses based on renal function; monitor renal function and serum amikacin levels closely; usual initial dose reduction to 7.5 mg/kg every 12-24 hours based on estimated GFR
Use with caution in elderly patients due to increased sensitivity to vasoconstrictive effects and higher risk of hypertension and myocardial ischemia.
Amikacin can cause nephrotoxicity and ototoxicity. The risk of nephrotoxicity is greater in patients with impaired renal function and those receiving high doses or prolonged therapy. Ototoxicity (both vestibular and auditory) can occur in patients with pre-existing renal damage and in those with normal renal function treated with higher doses or for longer periods than recommended.
Not for use during pregnancy (except during delivery) due to risk of uterine tetany and fetal hypoxia. Contraindicated in patients with hypertension, preeclampsia, or eclampsia due to risk of severe hypertension and stroke.
Neurotoxicity (ototoxicity) and nephrotoxicity; neuromuscular blockade; respiratory paralysis; cross-allergenicity among aminoglycosides; monitoring of renal function and drug levels recommended.
Risk of severe hypertension, especially in patients with preeclampsia, eclampsia, or hypertension.,Use with caution in patients with sepsis, hepatic or renal impairment, or coronary artery disease.,May cause ergotism with prolonged use or high doses (symptoms: vasospasm, ischemia).,Monitor blood pressure and uterine response during administration.
Hypersensitivity to amikacin or any aminoglycoside; history of ototoxicity with prior aminoglycoside use.
Hypersensitivity to ergot alkaloids,Pregnancy (for antepartum use),Hypertension, preeclampsia, or eclampsia,Peripheral vascular disease,Coronary artery disease,Severe hepatic or renal impairment,Sepsis
No significant food interactions. Maintain adequate hydration. Avoid alcohol as it may worsen side effects.
Avoid grapefruit juice as it may increase serum levels of methylergonovine via CYP3A4 inhibition. No specific food restrictions other than avoiding excessive caffeine intake, which may potentiate vasoconstrictive effects.
Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Animal studies have shown evidence of fetal harm (e.g., nephrotoxicity, ototoxicity) at doses similar to or lower than human doses. Amikacin crosses the placenta. First trimester: Risk cannot be excluded; use only if clearly needed. Second and third trimesters: Potential for fetal nephrotoxicity and ototoxicity; avoid use unless necessary for serious infections. Risk category D (positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience).
Methergine (methylergonovine) is contraindicated in pregnancy due to its oxytocic properties and risk of uterine hyperstimulation, fetal distress, and abortion. First trimester: potential teratogenic effects not well studied; avoid use. Second and third trimesters: can cause abruptio placentae, premature labor, and fetal anoxia. It is FDA Pregnancy Category X.
Amikacin is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.1-0.2. After intramuscular administration of 500 mg, peak milk concentrations are about 1-2 mcg/m L. Because of low oral bioavailability (poorly absorbed from the GI tract), systemic effects in the nursing infant are unlikely. However, theoretical risk of alteration of infant gut flora and direct exposure. Use with caution, especially in premature infants or those with renal impairment. The American Academy of Pediatrics considers amikacin compatible with breastfeeding.
Methylergonovine is excreted into breast milk in small amounts; the milk-to-plasma ratio is approximately 1.0. Adverse effects in nursing infants are rare but may include diarrhea, vomiting, and hypertension. It is generally considered compatible with breastfeeding when used short-term for postpartum hemorrhage. Avoid prolonged use.
Pharmacokinetic changes during pregnancy (e.g., increased volume of distribution, increased renal clearance) may require dose adjustments, but specific guidelines are not established. Generally, standard dosing based on actual body weight and renal function is used. Therapeutic drug monitoring is recommended, especially in third trimester or with concurrent renal impairment. Dose adjustments should be based on serum levels to maintain therapeutic efficacy while minimizing toxicity. No dose reduction is universally recommended; individualize based on renal function and clinical response.
Not applicable; the drug is contraindicated during pregnancy. No dose adjustments are recommended for use during pregnancy as it should not be used.
Monitor peak (20-30 mcg/m L) and trough (1-8 mcg/m L) serum levels; adjust dose based on renal function. Avoid concurrent use with other ototoxic/nephrotoxic drugs. Use extended-interval dosing (e.g., 15-20 mg/kg IV once daily) when possible. Assess for vestibular toxicity (ataxia, vertigo) and cochlear toxicity (tinnitus, high-frequency hearing loss).
METHERGINE (methylergonovine) is an ergot alkaloid used primarily for postpartum hemorrhage due to uterine atony. Do not use for routine induction of labor or for threatened abortion. Avoid in patients with hypertension, preeclampsia, coronary artery disease, or severe hepatic/renal disease. Monitor blood pressure closely during administration. Administer intramuscularly for rapid effect; onset is 2-5 minutes. Intravenous administration should be reserved for emergencies due to risk of hypertensive crisis. Contraindicated in pregnancy except immediately after delivery. Drug interactions: avoid concurrent use with strong CYP3A4 inhibitors (e.g., ketoconazole, macrolides, protease inhibitors) due to risk of ergotism and vasospasm. As of April 2025, there is no generic form; brand METHERGINE only.
Report any hearing loss, ringing in ears, dizziness, or unsteadiness immediately.,Drink plenty of fluids to help prevent kidney damage.,Avoid taking other aminoglycosides or strong diuretics unless prescribed.,Inform your doctor if you have kidney disease, myasthenia gravis, or are pregnant.
This medication is used to prevent or treat excessive bleeding after childbirth by causing contractions of the uterus.,Report immediately if you experience severe headache, chest pain, vision changes, muscle cramps, or numbness/tingling in the arms or legs.,Avoid breastfeeding within 8 hours after the last dose if possible; if breastfeeding is necessary, pump and discard for 8 hours to reduce infant exposure.,Do not use this medication if you have uncontrolled high blood pressure, heart disease, or liver/kidney disease.,Avoid alcohol and grapefruit juice while on this medication as they may affect blood levels.,Take this medication exactly as prescribed; do not take double doses if a dose is missed.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMIKIN vs METHERGINE, answered by our medical review team.
AMIKIN is a Aminoglycoside Antibiotic that works by Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibition of protein synthesis.. METHERGINE is a Ergot Alkaloid Uterotonic that works by Methylergonovine is an ergot alkaloid that acts as a partial agonist at α-adrenergic receptors in the uterine smooth muscle, causing sustained contractions. It also exhibits serotonergic (5-HT2) and dopaminergic activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMIKIN and METHERGINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMIKIN is: 15 mg/kg/day IV or IM divided every 8 to 12 hours; usual adult dose: 15 mg/kg/day. The standard adult dose of METHERGINE is: 0.2 mg intramuscularly or intravenously after delivery of placenta and every 2-4 hours as needed, up to a maximum of 5 doses.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMIKIN and METHERGINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMIKIN is classified as Category C. Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Animal studies have shown evidence of fetal harm (e.g., nephrotoxicit. METHERGINE is classified as Category C. Methergine (methylergonovine) is contraindicated in pregnancy due to its oxytocic properties and risk of uterine hyperstimulation, fetal distress, and abortion. First trimester: po. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.